Trader consensus at 78% against a new COVID variant of concern before 2027 stems primarily from ongoing surveillance showing that dominant lineages like XFG and NB.1.8.1 descendants continue to drive circulation without producing sharp rises in hospitalizations or deaths. Recent FDA approvals of updated 2026-2027 vaccines targeting XFG, alongside WHO assessments classifying only JN.1 as a variant of interest and others as variants under monitoring, underscore stable public health impact amid high population immunity from prior infections and shots. While BA.3.2 and similar sublineages display notable spike mutations and some immune evasion, their low prevalence and lack of severity signals have not triggered reclassification. Widespread genomic tracking and vaccine adaptation reduce the chance of sudden escalation in the remaining months of 2026, though gaps in global sequencing leave room for unexpected shifts.